A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis

Bone

Volumn 44, Issue 6, 2009, Pages 1078-1084

  Hagino, Hiroshi ^a   Nishizawa, Yoshiki ^b   Sone, Teruki ^c   Morii, Hirotoshi ^b   Taketani, Yuji ^d   Nakamura, Toshitaka ^e   Itabashi, Akira ^f   Mizunuma, Hideaki ^g   Ohashi, Yasuo ^h   Shiraki, Masataka ⁱ   Minamide, Toshiomi ^j   Matsumoto, Toshio ^k  

^a TOTTORI UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^f Saitama Livestock Research Center   (Japan)

^g HIROSAKI UNIVERSITY   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^j ONO PHARMACEUTICAL CO   (Japan)

^k UNIVERSITY OF TOKUSHIMA   (Japan)

more..

Author keywords

Alendronate; Bisphosphonate; BMD; Bone turnover markers; Minodronate

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; MINODRONIC ACID; OSTEOCALCIN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOT FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 67349251553     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.02.016     Document Type: Article

References (27)

1. Fleisch H. Bisphosphonates-preclinical. In: Fleisch H. (Ed). Bisphospjonates in bone disease: from the Laboratory to the patient (2000), Academic Press, New York 27-66
2. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2001) 235-242
3. Morii H., Nishizawa Y., Taketani Y., Nakamura T., Itabashi A., Mizunuma H., et al. A randomized controlled trial with ONO-5920 (minodronate/YM529) in Japanese patients with postmenopausal osteoporosis. J. Bone. Miner. Res. 17 Suppl (2002) S471
4. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., and Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone. Miner. Res. 17 (2002) 1-10
5. Bauer D.C., Black D.M., Garnero P., Hochberg M., Ott S., Orloff J., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J. Bone. Miner. Res. 19 (2004) 1250-1258
6. Orimo H., Sugioka Y., Fukunaga M., Muto Y., Hotokebuchi T., Gorai I., et al. Diagnostic criteria of primary osteoporosis. The Committee of the Japanese Society for Bone and Mineral Research for Development of Diagnostic Criteria of Osteoporosis. J. Bone. Miner. Metab. 16 (1998) 139-150
7. Orimo H., Hayashi Y., Fukunaga M., Sone T., Fujiwara S., Shiraki M., et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J. Bone. Miner. Metab. 19 (2001) 331-337
8. James I.T., Perrett D., and Thompson P.W. Rapid assay for hard tissue collagen cross-links using isocratic ion-pair reversed-phase liquid chromatography. J. Chromatogr. 525 (1990) 43-57
9. McAlister F.A., Laupacis A., Wells G.A., and Sackett D.L. Users' guides to the medical literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. Jama 282 (1999) 1371-1377
10. Bucher H.C., Guyatt G.H., Cook D.J., Holbrook A., and McAlister F.A. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. Jama 282 (1999) 771-778
11. Cranney A., Wells G., Willan A., Griffith L., Zytaruk N., Robinson V., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. 23 (2002) 508-516
12. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama 280 (1998) 2077-2082
13. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
14. Reid D.M., Hosking D., Kendler D., Brandi M.L., Wark J.D., Weryha G., et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS-International. Clin. Drug. Investig. 26 (2006) 63-74
15. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone. Miner. Res. 20 (2005) 141-151
16. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., and Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metab. 87 (2002) 1586-1592
17. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone. Miner. Res. 18 (2003) 1051-1056
18. Khosla S. Surrogates for fracture endpoints in clinical trials. J. Bone. Miner. Res. 18 (2003) 1146-1149
19. Shiraki M., Kushida K., Fukunaga M., Kishimoto H., Taga M., Nakamura T., et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos. Int. 10 (1999) 183-192
20. Uchida S., Taniguchi T., Shimizu T., Kakikawa T., Okuyama K., Okaniwa M., et al. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J. Bone. Miner. Metab. 23 (2005) 382-388
21. Fukunaga M., Kushida K., Kishimoto H., Shiraki M., Taketani Y., Minaguchi H., et al. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos. Int. 13 (2002) 971-979
22. Bone H.G., Downs Jr. R.W., Tucci J.R., Harris S.T., Weinstein R.S., Licata A.A., et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J. Clin. Endocrinol. Metab. 82 (1997) 265-274
23. Tucci J.R., Tonino R.P., Emkey R.D., Peverly C.A., Kher U., and Santora II A.C. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am. J. Med. 101 (1996) 488-501
24. Devogelaer J.P., Broll H., Correa-Rotter R., Cumming D.C., De Deuxchaisnes C.N., Geusens P., et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18 (1996) 141-150
25. Wasnich R.D., Ross P.D., Thompson D.E., Cizza G., and Yates A.J. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. Osteoporos. Int. 9 (1999) 455-460
26. Pols H.A., Felsenberg D., Hanley D.A., Stepan J., Munoz-Torres M., Wilkin T.J., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos. Int. 9 (1999) 461-468
27. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging. (Milano). 12 (2000) 1-12